Factors Associated With Additional Axillary Disease in Patients With Positive Sentinel Lymph Nodes After Neoadjuvant Chemotherapy for Breast Cancer

Discussion: Among patients with positive SLN after NAC, clinically node positive and ER+ HER2- patients were more likely to have nonSLN involvement. Our findings support guidelines to consider omitting cALND in clinically node negative patients. With improving NAC, optimal axillary sampling, and radiation, omitting cALND may be safe in some clinically node positive triple negative or HER2+ patients with low volume residual disease, but further research is needed.PMID:38716696 | DOI:10.1177/00031348241248813

Source: The American Surgeon - May 8, 2024 Category: Surgery Authors: Natalie C Johnson Hannah Kornfeld Lorena Gonzalez Hannah Mora Nikita Shah Veronica C Jones Katharine Schulz-Costello Source Type: research